SCHEMBL6170335

SCHEMBL6170335

CCCC1CN(C(Cc2cccc(Cl)c2)C(=O)NC)CCN1C(=O)C(N)Cc1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MC3R P41968 18/20 0.56
MC4R P32245 18/20 0.56
MC1R Q01726 17/20 0.56
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5844678 0.99 MC3R (0.55) MC3RMC4RMC1RHDAC8
Trifluoroacetic Acid SCHEMBL5845583 0.96 MC3R (0.53) MC3RMC4RMC1RHDAC8
SCHEMBL5844514 0.94 MC3R (0.59) MC3RMC4RMC1R
SCHEMBL6169250 0.92 MC3R (0.56) MC3RMC4RMC1R
Hydrochloric Acid SCHEMBL5845818 0.91 MC3R (0.56) MC3RMC4RMC1R
SCHEMBL19215620 0.91 MC3R (0.59) MC3RMC4RMC1R
SCHEMBL5843773 0.91 MC3R (0.58) MC3RMC4RMC1R
SCHEMBL5843764 0.91 MC3R (0.56) MC3RMC4RMC1R
SCHEMBL5844638 0.90 MC3R (0.57) MC3RMC4RMC1R
SCHEMBL5844709 0.90 MC3R (0.51) MC3RMC4RMC1RHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556361-A2 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2005-07-27 EP claimed
US-20050010031-A1 Melanocortin receptor ligands THE PROCTER & GAMBLE COMPANY 2005-01-13 US claimed
WO-2004037797-A2 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2004-05-06 WO claimed
US-20220143135-A1 INHIBITORS OF BCL-2 UNIV CASE WESTERN RESERVE (US) 2022-05-12 US disclosed
US-11229641-B2 Inhibitors of Bcl-2 CASE WESTERN RESERVE UNIVERSITY (US) 2022-01-25 US disclosed
US-20170224678-A1 INHIBITORS OF BCL-2 CASE WESTERN RESERVE UNIVERSITY 2017-08-10 US disclosed
US-20170224678-A1 INHIBITORS OF BCL-2 CASE WESTERN RESERVE UNIVERSITY 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010031-A1 Melanocortin receptor ligands MC3R, MC5R, MC1R MC3R 1/4885MC4R 8/4885MC1R 3/4885
US-20170224678-A1 INHIBITORS OF BCL-2 BCL2, BAX, BAK1 MC3R 3741/4885MC4R 4512/4885MC1R 4052/4885
US-11229641-B2 Inhibitors of Bcl-2 BCL2, BAX, BAK1 MC3R 3741/4885MC4R 4512/4885MC1R 4052/4885
US-20220143135-A1 INHIBITORS OF BCL-2 BCL2, BAX, BAK1 MC3R 3741/4885MC4R 4512/4885MC1R 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.